Fucosylated multiwalled carbon nanotubes for Kupffer cells targeting for the treatment of cytokine-induced liver damage

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 322-334

  Gupta, Richa ^a   Mehra, Neelesh Kumar ^a   Jain, Narendra Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

carbon nanotubes; fucose; Kupffer cells; liver targeting; sulfasalazine

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; MULTI WALLED NANOTUBE; PROTEIN P40; SALAZOSULFAPYRIDINE;

ACYLATION; AMIDATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARBOXYLATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE INDUCED LIVER DAMAGE; CYTOKINE RELEASE; DIALYSIS MEMBRANE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; EQUILIBRIUM DIALYSIS; FUCOSYLATION; HEMOLYSIS; KUPFFER CELL; LIVER INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; CELL LINE; CYTOKINES; DELAYED-ACTION PREPARATIONS; HUMANS; KUPFFER CELLS; LIVER DISEASES; MACROPHAGES; MALE; NANOTUBES, CARBON; RATS; RATS, SPRAGUE-DAWLEY; SULFASALAZINE;

EID: 84895489688     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1162-9     Document Type: Article

References (57)

1. Nishikori M. Classical and alternative NF-κB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol. 2005;45(1):15-24.
2. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Investig. 2001;107(1):7-11.
3. Robinson SM, Man DA. Role of nuclear factor κB in liver health and disease. Clin Sci. 2010;118:691-705.
4. Tsukamoto H. Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal. 2002;4:741-8.
5. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem. 1990;192:245-61.
6. Handa O, Naito Y, Takagi T, Shimozawa M, Kokura S, Yoshida N, et al. Tumor necrosis factor-alpha-induced cytokine-induced neutrophil chemoattractant-1 (CINC-1) production by rat gastric epithelial cells: role of reactive oxygen species and nuclear factor-kB. J Pharmacol Exp Ther. 2004;309:670-6.
7. Travis SPL, Jewell DP. Salicylates for ulcerative colitis-their mode of action. Pharmacol Ther. 1994;63:135-61.
8. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Investig. 1998;101(5):1163-74.
9. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-κB): an emerging theme in anti-inflammatory therapies. Mol Interv. 2002;2(1):22-35.
10. Schorder H, Campbell DES. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972;13:539-51.
11. Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, Hashida M. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim Biophys Acta. 2002;1524:258-65.
12. Mehra NK, Jain AK, Lodhi N, Raj R, Dubey V, Mishra DK, et al. Challenges in the use of carbon nanotubes for biomedical applications. Crit Rev Ther Drug Carrier Syst. 2008;25(2):169-220.
13. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Exp Opin Drug Deliv. 2013;10(3):353-67.
14. Jain AK, Mehra NK, Lodhi N, Dubey V, Mishra D, Jain NK. Carbon nanotubes and their toxicity. Nanotoxicol. 2007;1:167-97.
15. Mehra NK, Mishra V, Jain NK. Receptor-based targeting of therapeutics. Ther Deliv. 2013;4(3):369-94.
16. Kesharwani P, Ghanghoria R, Jain NK. Carbon nanotubes exploration in cancer cell lines. Drug Discov Today. 2012;17(17-18):1023-30.
17. Montes-Fonseca SL, Orrantia-Borunda E, Aguilar-Elguezabal A, Gonzalez Horta C, Talamas-Rohana P. Cytotoxicity of functionalized carbon nanotubes in J774A macrophages. Nanomed Nanotechnol Biol Med. 2012;8:853-9.
18. Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials. 2012;33(6):1689-98.
19. Jain AK, Dubey V, Mehra NK, Lodhi N, Nahar M, Mishra DK, et al. Carbohydrate-conjugated multiwalled carbon nanotubes: development and characterization. Nanomed Nanotechnol Biol Med. 2009;5(4):432-42.
20. Lacerda L, Russier J, Pastorin G, Herrero MA, Venturelli E, Dumortier H, et al. Translocation mechanisms of chemically functionalized carbon nanotubes across plasma membranes. Biomaterials. 2012;33:3334-43.
21. Zhang X, Meng L, Lu Q, Fei Z, Dyson PJ. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials. 2009;30:6041-7.
22. Ji Z, Lin G, Lu Q, Meng L, Shen X, Dong L, et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci. 2012;365:143-9.
23. Pruthi J, Mehra NK, Jain NK. Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes. J Drug Target. 2012;20(7):593-604.
24. Lodhi N, Mehra NK, Jain NK. Development and characterization of dexamethasone mesylate anchored on multi walled carbon nanotubes. J Drug Target. 2013;21(1):67-76.
25. Higuchi Y, Kawakami S, Yamashita F, Hashida M. The potential role of fucosylated cationic liposome/NF-κB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials. 2007;28:532-9.
26. Zheng B, Li Y, Liu J. CVD synthesis and purification of single walled carbon nanotubes on aerogel-supported catalyst. Appl Phys A. 2002;74:345-8.
27. Li CC, Lin JC, Huang SJ, Lee JT, Chen CH. A new and acid exclusive method for dispersing multi-walled carbon nanotubes in aqueous suspensions. Colloids Surf A Physicochem Eng Asp. 2007;297:275-81.
28. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res. 2009;26:2588-98.
29. Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidised multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33:3324-33.
30. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;57:111-24.
31. Jain V, Swarnakar NK, Mishra PR, Verma A, Kaul A, Mishra AK, et al. Paclitaxel loaded PEGylated glyceryl monooleate based nanoparticulate carriers in chemotherapy. Biomaterials. 2012;33(29):7206-20.
32. Agrawal A, Gupta U, Asthana A, Jain NK. Dextran conjugated dendrite nanoconstructs as potential vectors for anti-cancer agent. Biomaterials. 2009;30:3588-96.
33. Gajbhiye V, Jain NK. The treatment of Glioblastom a xenografts by surfactant conjugated de ndritic nanoconjugates. Biomaterials. 2011;32(26):6213-25.
34. Patel SK, Gajbhiye V, Jain NK. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J Drug Target. 2012;20(10):841-9.
35. Duverger A, Jackson RJ, Van Ginkel FW, Fischer R, Tafaro A, Leppla SH, et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol. 2006;176(3):1776-83.
36. Houghton P, Fang R, Techatanawat I, Steventon G, Hylands PJ, Lee CC. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods. 2007;42:377-87.
37. Perez RP, Godwin A, Handel LM, Hamilton TC. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer. 1993;29A(3):395-9.
38. Singodia D, Verma A, Verma RK, Mishra PR. Investigations on alternate approach to target mannose receptors on macrophages using 4-sulfated n-acetyl galactosamine more efficiently as compared to mannose decorated liposomes: an application in drug delivery. Nanomed Nanotechnol Biol Med. 2012;8(4):468-77.
39. Haskoa G, Szaboa C, Neameth ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology. 2001;103:473-8.
40. Newkome GR, Woosley BD, He E, Moorefield CN, Guther R, Baker GR, et al. Supramolecular chemistry of flexible, dendritic based structures employing molecular recognition. Chem Commun. 1996;24:2737-8.
41. Rodenburg RJT, Ganga A, Van Lent PLEM, Van De Putte LBA, Van Venrooij WJV. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor α expression in macrophages by inducing apoptosis. Arthritis Rheum. 2000;43(9):1941-50.
42. Jianquin C. Determination of sulfasalazine tablets by HPLC. Chin Pharm Aff. 2007;08-13.
43. Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials. 2007;28:3349-59.
44. Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm. 2010;393(1-2):185-96.
45. Newkome GR, Moorefield CN, Baker GR, Saunders MJ, Grossman SH. Unimolekulare micellen. Angew Chem Int Ed. 1991;103:1207-9.
46. More N, Vander Kolk JV, Heifets I. Accumulation of clarithromycin in macrophages infected with M. avium. Pharmacol Ther. 1994;14:100-4.
47. Gu YJ, Cheng J, Jin J, Cheng SH, Wong WT. Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells. Int J Nanomedicine. 2011;6:2889-98.
48. Bawa R. Regulating nanomedicines-can the FDA handle it? Curr Drug Deliv. 2011;8(3):227-34.
49. Wang Y, Iqbal Z, Malhotra SV. Functionalization of carbon nanotubes with amines and enzymes. Chem Phys Lett. 2005;402(1-3):96-101.
50. Chen Z, Hagler J, Palombella VJ, Melandri F, Seherer D, Ballard D, et al. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 1995;9:1586-97.
51. Yeeprae W, Kawakami S, Yamashita F, Hashida M. Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. J Control Release. 2006;114(2):193-201.
52. Meng J, Yang M, Jia F, Xu Z, Kong H, Xu H. Immune response of BALB/c mice to subcutaneously injected multi-walled carbon nanotubes. Nanotoxicol. 2010;5(4):583-9.
53. Jain S, Thakare VS, Das M, Godugu C, Jain AK, Mathur R, et al. Toxicity of multi walled carbon nanotubes with end defects critically depends on their functionalization density. Chem Res Toxicol. 2011;24(11):2028-39.
54. Schipper ML, Nakayama-Ratchford N, Davis CR, Kam NWS, Chu P, Liu Z, et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol. 2008;3(4):216-21.
55. Garg M, Jain NK. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target. 2006;14(1):1-11.
56. Lu YJ, Wei KC, Ma CCM, Yang SY, Chen JP. Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces. 2012;89:1-9.
57. Singh R, Mehra NK, Jain V, Jain NK. Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells. J Drug Target. 2013;21(6):581-92.